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OBJECTIVE: Erlotinib, a novel targeted anticancer therapy,
improves survival and quality of life (QoL) in patients with
advanced NSCLC after chemotherapy failure. The incremental
cost effectiveness ratio (ICER) of erlotinib based on a random-
ized placebo-controlled trial, (NCIC CTG BR.21) is $95,869
(2007 CDN), per life-year gained (LYG). Here we perform a cost
utility analysis (CUA) of erlotinib in patients with advanced
NSCLC, and explore novel methodology to utilize QoL data
collected using the EORTC QLQC30 tool. METHODS: Previ-
ously published resource utilization and QoL data from patients
recruited as part of the NCIC CTG BR.21 clinical trial were used.
Utility weights were derived from the prospective collection of
the EQ5D in a separate cohort of advanced NSCLC patients
receiving erlotinib or supportive care alone. QoL was also pro-
spectively collected using the EORTC QLQC30. Correlation
between utility (EQ5D) and QoL in the cohort is being explored,
and will be applied to published QoL data from the NCIC CTG
BR.21 trial data. RESULTS: Prospective data from the EQ5D
and EORTC QLQC30 were obtained from 64 patients with
NSCLC, 31 receiving erlotinib and 33 supportive care. The mean
utility derived for those treated with erlotinib was 0.772, and for
those not receiving erlotinib was 0.754. The mean incremental
cost of erlotinib over supportive care was previously derived as
$12,303, mean survival 0.13 years, and quality-adjusted survival
improvement with erlotinib treatment in advanced NSCLC based
on published data from the NCIC CTG BR.21 trial was esti-
mated at 0.11 QALY, with an ICER estimated at approximately
$110,321 per QALY CONCLUSION: The cost utility of erlo-
tinib in patients with advanced NSCLC is estimated at $110,321
per QALY (CDN$ 2007); a parallel investigation to evaluate
methodology to utilize EORTC QLQ30 QoL data is underway.
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TIME COSTS AND OUT-OF-POCKET COSTS OF PROSTATE
CANCER SURVIVORS IN ONTARIO, CANADA
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OBJECTIVE: To estimate out-of-pocket costs (OPC) and time
costs (TC) for prostate cancer (PC) care in PC survivors.
METHODS: Surviving PC patients residing in Ontario, and diag-
nosed in 1993–4, 1997–8, or 2001–2, were selected from the
Ontario Cancer Registry (n = 1961). A self-report questionnaire
was completed, which asked about health care and lost time
associated with PC in eight key areas: 1) health care professional
visits, and accompanying person; 2) medication use; 3) equip-
ment purchased; 4) community service use; 5) employment time
lost; 6) problems with household chores; 7) leisure time lost;
and 8) health care insurance. Time was valued according to the
average hourly wage in 2006 in Canada. RESULTS: 670 patients
returned completed questionnaires. The mean annual OPC and
TC of PC care was $1093/patient. Mean annual OPC were
estimated to be $349/patient. Patients incurred an average of
$319 annually for health professional visits and diagnostic tests.
Sixty-nine percent (n = 462) of patients visited at least one health
care professional; 43% visited an urologist, 18% visited a family
physician, and 15% visited a radiation oncologist. Individuals
who visited a radiation oncologist incurred the greatest mean
annual TC ($289), followed by patients who visited an urologist
($223) and family physician ($151). Only 26% of patients were
employed for pay; 5 patients reported difﬁculty working. Mean
annual productivity loss was estimated at $225 per patient.
CONCLUSION: TC associated with work loss does not repre-
sent a major economic burden among PC patients because a
minority are working, and impact among those who work is
modest. OPC, in a country with universal health insurance, is
similar in magnitude to the annual attributable direct medical
costs among stable PC outpatients ($349 vs. $303). Data from
this study will be used, along with outcome data gathered from
the same patients, to develop a Canadian PC policy model.
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EFFECT OF DEMOGRAPHIC FACTORS AND SOCIAL
ECONOMICVARIABLES ON HEALTH CARE RESOURCE
UTILIZATION AND EXPENDITURE FOR BREAST CANCER
PATIENTS USING MEPS 2004
Zhan L, Nair RR, Black CD, Pinto SL, Holiday-Goodman M
The University of Toledo,Toledo, OH, USA
OBJECTIVE: To examine the inﬂuences of demographic and
socioeconomic factors on the health care resource utilization
and expenditure for breast cancer patients in MEPS 2004.
METHODS: A retrospective secondary database study was
conducted using the 2004 Medical Expenditure Panel Survey
(MEPS). Patients with breast cancer  18 years (ICD-9-
CM = 174, 175, V10.3, 233 and CCC code = 024) were included
in the analysis. Poisson regression and Generalized Linear-
Gamma model were employed to examine how demographics
and socioeconomics variables predicted the difference in total
health care resource utilization and total expenditure. In order to
generalize the results to the whole U.S. population, sample
weight from MEPS was utilized. RESULTS: A total of 121 female
patients were included in the study. Approximately 52.9% of
them were over 65 years old; 85.1% were Caucasian women;
52.9% were married; 27.3% had Bachelor’s degree or above;
76.0% were urban; 62.0% were unemployed; 67.8% had high
family income; 97.5% had insurance. Caucasian women in the
age group 50–64, who were living in the rural area and had lower
family income, utilized more health care resources. Employment
and family size were not found to signiﬁcantly inﬂuence health
care resource utilization. CONCLUSION: This study provides
insight into factors related to health care resource utilization and
expenditure. Demographic and socioeconomic factors did inﬂu-
ence health care resource and expenditure differently. This study
may help policy makers in optimal decision-making based on the
factors included in the study. Future studies can look into other
factors such as treatment regimen, stage of the disease to explain
differences in health care resource utilization and expenditure
patterns.
CANCER—Patient-Reported Outcomes
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EARLY DISCONTINUATION OF ADJUVANT ENDOCRINE
TREATMENT OF BREAST CANCER
Bowen KL, Owerbach J
Excellus BlueCross BlueShield, Rochester, NY, USA
OBJECTIVE: To estimate the rate of early discontinuation of
oral adjuvant endocrine therapy by women with early-stage
breast cancer in a commercially insured population. METHODS:
The study sample consists of all women from a commercially
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